IP Library › Granted Patent US 12698530
Granted Patent B2
US 12698530 · App. 17/748,110 · Granted Aug 4, 2026

Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

Inventors: Luca Andrea Lotta (Tarrytown, NY); Manuel Allen Revez Ferreira (Tarrytown, NY); Aris Baras (Tarrytown, NY); Parsa Akbari (Tarrytown, NY); Olukayode Sosina (Tarrytown, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12Q1/6883A61K31/7105A61K38/465A61P3/04C12N15/1138C12N2310/11C12N2310/14C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698530
App. No.
17/748,110
Granted
Aug 4, 2026
Kind
B2
Abstract

The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.

Claims (25)

1 . A method of treating an obese subject, the method comprising administering a G-Protein Coupled Receptor 75 (GPR75) inhibitor to the obese subject,

wherein the obese subject has been determined to not be heterozygous or homozygous for a GPR75 missense variant nucleic acid molecule encoding a predicted loss-of-function GPR75, polypeptide;

wherein the GPR75 inhibitor comprises a inhibitory nucleic acid molecule.

2 . The method according to claim 1 , wherein the GPR75 inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule that hybridizes to a GPR75 mRNA.

3 . The method according to claim 1 , wherein the GPR75 inhibitory nucleic acid molecule comprises a small interfering RNA (siRNA) that hybridizes to a GPR75 mRNA.

4 . The method according to claim 1 , wherein the GPR75 inhibitory nucleic acid molecule comprises a short hairpin RNA (shRNA) that hybridizes to a GPR75 mRNA.

5 . The method according to claim 2 , wherein the obese subject is also administered liraglutide.

6 . The method according to claim 3 , wherein the obese subject is also administered liraglutide.

7 . The method according to claim 4 , wherein the obese subject is also administered liraglutide.

8 . The method according to claim 2 , wherein the obese subject is also administered exenatide.

9 . The method according to claim 3 , wherein the obese subject is also administered exenatide.

10 . The method according to claim 4 , wherein the obese subject is also administered exenatide.

11 . The method according to claim 2 , wherein the obese subject is also administered lixisenatide.

12 . The method according to claim 3 , wherein the obese subject is further administered lixisenatide.

13 . The method according to claim 4 , wherein the obese subject is further administered lixisenatide.

14 . The method according to claim 2 , wherein the obese subject is also administered albiglutide.

15 . The method according to claim 3 , wherein the obese subject is also administered albiglutide.

16 . The method according to claim 4 , wherein the obese subject is also administered albiglutide.

17 . The method according to claim 2 , wherein the obese subject is also administered dulaglutide.

18 . The method according to claim 3 , wherein the obese subject is also administered dulaglutide.

19 . The method according to claim 4 , wherein the obese subject is also administered dulaglutide.

20 . The method according to claim 2 , wherein the obese subject is also administered semaglutide.

21 . The method according to claim 3 , wherein the obese subject is also administered semaglutide.

22 . The method according to claim 4 , wherein the obese subject is also administered semaglutide.

23 . The method according to claim 1 , wherein the obese subject is a human.